MT Newswires
Leerink Partners Adjusts Edwards Lifesciences PT to $87 From $88, Maintains Market Perform Rating
➖
AI Sentiment
Neutral
5/10
- Home
- EW
as of 12-09-2025 3:57pm EST
$83.17
$1.15
-1.36%
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Chart Type:
Time Range:
| Founded: | 1958 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 45.5B | IPO Year: | 2000 |
| Target Price: | $94.89 | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.33 | EPS Growth: | -66.20 |
| 52 Week Low/High: | $65.94 - $87.89 | Next Earning Date: | 10-30-2025 |
| Revenue: | $5,883,800,000 | Revenue Growth: | 10.60% |
| Revenue Growth (this year): | 14.26% | Revenue Growth (next year): | 9.77% |
AI-Powered EW Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.16%
76.16%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Edwards Lifesciences Corporation (EW)
Markowitz Wayne
Sell
CVP, JAPAC
EW Dec 8, 2025
Avg Cost/Share
$86.01
Shares
583
Total Value
$50,143.83
Owned After
17,562.871
SEC Form 4
Ullem Scott B.
Sell
CVP, Chief Financial Officer
EW Nov 10, 2025
Avg Cost/Share
$83.16
Shares
13,000
Total Value
$1,080,093.43
Owned After
49,924
Lippis Daniel J.
Sell
CVP, JAPAC
EW Nov 10, 2025
Avg Cost/Share
$82.55
Shares
1,020
Total Value
$84,196.00
Owned After
22,001.91
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Markowitz Wayne | EW | CVP, JAPAC | Dec 8, 2025 | Sell | $86.01 | 583 | $50,143.83 | 17,562.871 | |
| Ullem Scott B. | EW | CVP, Chief Financial Officer | Nov 10, 2025 | Sell | $83.16 | 13,000 | $1,080,093.43 | 49,924 | |
| Lippis Daniel J. | EW | CVP, JAPAC | Nov 10, 2025 | Sell | $82.55 | 1,020 | $84,196.00 | 22,001.91 |
Latest Edwards Lifesciences Corporation News
EW Breaking Stock News: Dive into EW Ticker-Specific Updates for Smart Investing
Simply Wall St.
Will Edwards Lifesciences’ (EW) Upgraded 2025–2026 Outlook Reshape Its Long-Term Growth Narrative?
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Edwards Lifesciences (EW): Reassessing Valuation After Upbeat 2025–2026 Outlook and TAVR Growth Signals
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Edwards Lifesciences' Long-term Business Outlook Appears Achievable, RBC Says
➖
AI Sentiment
Neutral
5/10
MT Newswires
Raymond James Adjusts PT on Edwards Lifesciences to $100 From $96, Maintains Outperform Rating
📊
AI Sentiment
Positive
6/10
MT Newswires
UBS Adjusts Price Target on Edwards Lifesciences to $92 From $90, Maintains Neutral Rating
📊
AI Sentiment
Positive
6/10
MT Newswires
Truist Securities Adjusts PT on Edwards Lifesciences to $92 From $90, Maintains Hold Rating
➖
AI Sentiment
Neutral
5/10
Compare EW vs Leading Stocks
See how EW stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EW Edwards Lifesciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.